Pediatric reauthorization
Executive Summary
Pediatric exclusivity incentives for off-patent drugs are likely to be part of legislation expected in April from Sens. Dodd (D-Conn.) and Dewine (R-Ohio) to reauthorize pediatric provisions in FDA Modernization Act. The bill will likely run for six years to put pediatric provisions on same timeline as the Prescription Drug User Fee Act